Symbicort is a prescription drug used to treat asthma and chronic obstructive pulmonary disease (COPD). Learn how to lower long-term costs and more.

There is ongoing patent litigation between AstraZeneca, the maker of Symbicort, and Viatris, formerly known as Mylan Pharmaceuticals, and its drug delivery device partner Kindeva Drug Delivery LP.

Viatris announced the launch of Breyna ™ (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first generic version of AstraZeneca’s Symbicort ®.. Breyna is a metered-dose ...

The U.S. Food and Drug Administration said yesterday that it has given approval for the first generic of the Symbicort inhaler to treat asthma and COPD. Symbicort is a combination of budesonide ...

The first Symbicort generic, simply referred to as budesonide/formoterol inhaler, was approved by the Food and Drug Administration (FDA) in February 2020 and is roughly half the cost of Symbicort.

Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the ...

With tentative approval from the Food and Drug Administration, Viatris faces a legal battle to bring the generic to market and has not planned for any revenue from the product for 2021.

Still, for AstraZeneca's respiratory franchise, the approval is welcome news. Aging Symbicort won't be able to keep up its $3.44-billion-a-year-act forever, and pipeline prospect benralizumab ...

Symbicort uses the corticosteroid budesonide, while Advair contains fluticasone. The long-acting beta 2 -adrenergic agonist in either drug helps relax the muscles around the airways in your lungs.